JP2016514713A - クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン - Google Patents

クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン Download PDF

Info

Publication number
JP2016514713A
JP2016514713A JP2016503549A JP2016503549A JP2016514713A JP 2016514713 A JP2016514713 A JP 2016514713A JP 2016503549 A JP2016503549 A JP 2016503549A JP 2016503549 A JP2016503549 A JP 2016503549A JP 2016514713 A JP2016514713 A JP 2016514713A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
polypeptide
chlamydia
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514713A5 (enExample
Inventor
フォルマン，フランク
ローゼンクランツ，イーダ
オールセン，アニャ
アンデルセン，ペーター，ラヴェツ
Original Assignee
スタテンス セールム インスティトゥート
スタテンス セールム インスティトゥート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スタテンス セールム インスティトゥート, スタテンス セールム インスティトゥート filed Critical スタテンス セールム インスティトゥート
Publication of JP2016514713A publication Critical patent/JP2016514713A/ja
Publication of JP2016514713A5 publication Critical patent/JP2016514713A5/ja
Priority to JP2019052389A priority Critical patent/JP7510142B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016503549A 2013-03-18 2014-03-17 クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン Pending JP2016514713A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019052389A JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300155 2013-03-18
DKPA201300155 2013-03-18
DKPA201300684 2013-12-11
DKPA201300684 2013-12-11
PCT/DK2014/000015 WO2014146663A1 (en) 2013-03-18 2014-03-17 Vaccines against chlamydia sp.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019052389A Division JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Publications (2)

Publication Number Publication Date
JP2016514713A true JP2016514713A (ja) 2016-05-23
JP2016514713A5 JP2016514713A5 (enExample) 2017-04-13

Family

ID=50639248

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503549A Pending JP2016514713A (ja) 2013-03-18 2014-03-17 クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン
JP2019052389A Active JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
JP2021148819A Active JP7506930B2 (ja) 2013-03-18 2021-09-13 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019052389A Active JP7510142B2 (ja) 2013-03-18 2019-03-20 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
JP2021148819A Active JP7506930B2 (ja) 2013-03-18 2021-09-13 クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン

Country Status (20)

Country Link
US (4) US20140275478A1 (enExample)
EP (1) EP2976355B1 (enExample)
JP (3) JP2016514713A (enExample)
CN (2) CN113185587A (enExample)
AU (1) AU2014234765B2 (enExample)
BR (1) BR112015023886B1 (enExample)
CA (1) CA2907199C (enExample)
CY (1) CY1122905T1 (enExample)
DK (1) DK2976355T3 (enExample)
ES (1) ES2781579T3 (enExample)
HR (1) HRP20200511T1 (enExample)
HU (1) HUE048573T2 (enExample)
LT (1) LT2976355T (enExample)
PL (1) PL2976355T3 (enExample)
PT (1) PT2976355T (enExample)
RS (1) RS60135B1 (enExample)
RU (1) RU2723046C2 (enExample)
SI (1) SI2976355T1 (enExample)
SM (1) SMT202000160T1 (enExample)
WO (1) WO2014146663A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510829A (ja) * 2017-03-02 2020-04-09 ビオスパーク・ベー・フェーＢｉｏｓｐａｒｑ Ｂ．Ｖ． 診断方法および診断システム
JP2024500237A (ja) * 2020-12-23 2024-01-05 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 抗原提示細胞に対するｍｏｍｐ ｖｓ４抗原の標的化に基づくクラミジアワクチン

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10688171B2 (en) 2015-02-10 2020-06-23 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
CN104800841B (zh) * 2015-03-02 2019-04-02 中国农业科学院兰州兽医研究所 牦牛流产衣原体灭活疫苗及其制备方法
EP3274716B1 (en) 2015-03-24 2019-05-08 Universiteit Gent A method and peptides for the detection of chlamydia suis
WO2017075653A1 (en) * 2015-11-04 2017-05-11 University Of The Sunshine Coast Chlamydia antigens and uses thereof
US10835601B2 (en) 2015-11-10 2020-11-17 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
CA3057318A1 (en) * 2017-03-23 2018-09-27 Ohio State Innovation Foundation Recombinant chlamydia-activated b cell platforms and methods of use thereof
RU2721123C1 (ru) * 2019-09-26 2020-05-18 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Штамм рекомбинантной псевдоаденовирусной частицы, экспрессирующий химерный ген MBL-CT666 Chlamydia trachomatis, способ его получения, иммуногенная композиция для защиты от урогенитального хламидиоза человека
CN116854812B (zh) * 2022-03-23 2024-09-24 东莞市朋志生物科技有限公司 抗沙眼衣原体的抗体、检测沙眼衣原体的试剂和试剂盒
CN115975049A (zh) * 2022-11-12 2023-04-18 北京成大天和生物科技有限公司 一种沙眼衣原体重组蛋白及其制备方法和应用
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
WO2025104023A1 (en) 2023-11-13 2025-05-22 Ziphius Nv MODIFIED ALPHAVIRAL nsP3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002506A1 (en) * 1992-07-24 1994-02-03 The School Of Pharmacy, University Of London Peptide compounds
JP2001502887A (ja) * 1996-08-09 2001-03-06 ユニバーシティ オブ サスカッチェワン ＧｎＲＨ―ロイコトキシンキメラ
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
WO2012172042A1 (en) * 2011-06-17 2012-12-20 Universiteit Gent Vaccines for chlamydia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5869608A (en) 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
EP0662083A1 (en) 1992-09-18 1995-07-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Synthetic peptide vaccine for chlamydia trachomatis
GB9516293D0 (en) * 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
JP4896715B2 (ja) * 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
EP1812058B1 (en) * 2004-10-25 2012-06-13 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
AU2006247188A1 (en) * 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
TW201012929A (en) * 2008-09-29 2010-04-01 Univ Nat Pingtung Sci & Tech A hybridoma cell line producing monoclonal antibodies against chalmydophila aborts
AU2010207828B2 (en) * 2009-01-29 2016-07-14 British Columbia Cancer Agency Branch Compositions comprising Chlamydia antigens
US8735543B2 (en) * 2010-05-28 2014-05-27 Spixia Biotechnology Ab Chimeric MOMP antigen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002506A1 (en) * 1992-07-24 1994-02-03 The School Of Pharmacy, University Of London Peptide compounds
JP2001502887A (ja) * 1996-08-09 2001-03-06 ユニバーシティ オブ サスカッチェワン ＧｎＲＨ―ロイコトキシンキメラ
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
WO2012172042A1 (en) * 2011-06-17 2012-12-20 Universiteit Gent Vaccines for chlamydia

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AHN, T. AND YUN, C.-H., BMB REPORTS, vol. 42, no. 7, JPN6018045568, 2009, pages 418 - 420, ISSN: 0003921154 *
BAEHR, W. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, JPN6017046391, 1988, pages 4000 - 4004, ISSN: 0003696097 *
BATTEIGER, B.E. ET AL., INFECT. IMMUN., vol. 64, JPN6017046375, 1996, pages 2839 - 2841, ISSN: 0003696088 *
BATTEIGER, B.E., INFECT. IMMUN., vol. 64, JPN6017046389, 1996, pages 542 - 547, ISSN: 0003696096 *
BROEKHUIJSEN, M.P. ET AL., J. GEN. VIROL., vol. 68, JPN6017046368, 1987, pages 3137 - 3143, ISSN: 0003696085 *
FOLLMANN, F. ET AL., J. INFECT. DIS., vol. 197, JPN6018045571, 2008, pages 897 - 905, ISSN: 0003921156 *
KALBINA, I. ET AL., PROTEIN EXPR. PURIF., vol. 80, JPN6017046369, 2011, pages 194 - 202, ISSN: 0003696086 *
KIM, S.-K. AND DEMARS, R. ET AL., CURR. OPIN. IMMUNOL., vol. 13, JPN6017046372, 2001, pages 429 - 436, ISSN: 0003696087 *
MYGIND, P. ET AL., J. MED. MICROBIOL., vol. 49, JPN6017046362, 2000, pages 457 - 465, ISSN: 0003696083 *
PAL, S. ET AL., J. GEN. MICROBIOL., vol. 139, JPN6017046377, 1993, pages 1565 - 1570, ISSN: 0003696089 *
PETERSON, E.M. ET AL., INFECT. IMMUN., vol. 64, JPN6017046392, 1996, pages 3354 - 3359, ISSN: 0003696090 *
PETERSON, E.M. ET AL., MOL. IMMUNOL., vol. 33, JPN6017046378, 1996, pages 335 - 339, ISSN: 0003696091 *
QU, Z. ET AL., VACCINE, vol. 12, JPN6017046365, 1994, pages 557 - 564, ISSN: 0003696084 *
SU, H. ET AL., J. EXP. MED., vol. 172, JPN6017046385, 1990, pages 203 - 212, ISSN: 0003696094 *
TIFREA, D.F. ET AL., INFECT. IMMUN., vol. 81, JPN6017046381, 2013, pages 1741 - 1750, ISSN: 0003696092 *
TOYE, B. ET AL., INFECT. IMMUN., vol. 58, JPN6017046383, 1990, pages 3909 - 3913, ISSN: 0003696093 *
VILLENEUVE, A. ET AL., MICROBIOLOGY, vol. 140, JPN6017046387, 1994, pages 2481 - 2487, ISSN: 0003696095 *
WANG, J. ET AL., J. IMMUNOL., vol. 185, JPN6018045572, 2010, pages 1670 - 1680, ISSN: 0003921157 *
YU, J.-R. ET AL., J. VIROL., vol. 82, no. 5, JPN6018045566, 2008, pages 2350 - 2357, ISSN: 0003921153 *
広辞苑, vol. 第5版, JPN6018045570, 1998, pages 1441, ISSN: 0003921155 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510829A (ja) * 2017-03-02 2020-04-09 ビオスパーク・ベー・フェーＢｉｏｓｐａｒｑ Ｂ．Ｖ． 診断方法および診断システム
JP2024500237A (ja) * 2020-12-23 2024-01-05 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 抗原提示細胞に対するｍｏｍｐ ｖｓ４抗原の標的化に基づくクラミジアワクチン

Also Published As

Publication number Publication date
JP2021193123A (ja) 2021-12-23
EP2976355A1 (en) 2016-01-27
WO2014146663A1 (en) 2014-09-25
JP7506930B2 (ja) 2024-06-27
DK2976355T3 (en) 2020-03-30
PL2976355T3 (pl) 2020-07-13
CN105377879A (zh) 2016-03-02
US20190099478A1 (en) 2019-04-04
CN113185587A (zh) 2021-07-30
JP2019163253A (ja) 2019-09-26
HUE048573T2 (hu) 2020-08-28
RU2015141214A (ru) 2017-04-26
AU2014234765B2 (en) 2018-01-25
CN105377879B (zh) 2021-05-04
HRP20200511T1 (hr) 2020-06-26
CA2907199A1 (en) 2014-09-25
ES2781579T3 (es) 2020-09-03
SMT202000160T1 (it) 2020-05-08
EP2976355B1 (en) 2020-01-01
BR112015023886B1 (pt) 2023-05-16
AU2014234765A1 (en) 2015-10-08
US20140275478A1 (en) 2014-09-18
SI2976355T1 (sl) 2020-07-31
US10925954B2 (en) 2021-02-23
US20250255951A1 (en) 2025-08-14
US20210205433A1 (en) 2021-07-08
JP7510142B2 (ja) 2024-07-03
RS60135B1 (sr) 2020-05-29
LT2976355T (lt) 2020-04-10
PT2976355T (pt) 2020-04-02
CY1122905T1 (el) 2021-10-29
BR112015023886A2 (pt) 2017-10-24
CA2907199C (en) 2023-10-17
RU2723046C2 (ru) 2020-06-08

Similar Documents

Publication Publication Date Title
JP7506930B2 (ja) クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
de la Maza et al. Update on Chlamydia trachomatis vaccinology
Jiang et al. Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model
Sun et al. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein
Igietseme et al. Chlamydia vaccines: strategies and status
Yu et al. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice
JP2012180367A (ja) クラミジア感染に対するワクチン
JP2008544745A (ja) Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓのための免疫原性組成物
US8889142B2 (en) Chlamydia trachomatis antigens for vaccine and diagnostic use
US20100310593A1 (en) Vaccines Against Chlamydia Infection
Pal et al. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge
Tifrea et al. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis
JP2007526318A (ja) Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫原性組成物
US20210093703A1 (en) Recombinant expression of chlamydia momp antigen
RU2721123C1 (ru) Штамм рекомбинантной псевдоаденовирусной частицы, экспрессирующий химерный ген MBL-CT666 Chlamydia trachomatis, способ его получения, иммуногенная композиция для защиты от урогенитального хламидиоза человека
CN1984678A (zh) 用于肺炎衣原体的免疫原性组合物
Poston T-cell Dependent and independent mechanisms of chlamydial eradication and control
Olsen et al. Protection against Chlamydia Promoted by a Subunit Vaccine (CTH1) Compared
Tammiruusu CD8+ T Cell Response in Experimental Chlamydia pneumoniae Infection
as an Adjuvant et al. Immunization with the

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20151110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181120